The overturning of the FDA’s lab-developed tests rule is just the tip of the iceberg. With the loss of Chevron deference, ...

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

When investing on a budget, buying fractional shares of top companies is one option. Two great options right now are Novo ...

The pipeline battle is far from over. Novo Nordisk is betting on CagriSema and next-generation amycretin-based therapies, which target multiple gut hormones to amplify weight-loss effects. Meanwhile, ...

Health workers have long relied on Body Mass Index as a way to measure whether people are within a healthy weight range. Now, a collection of top researchers have made the case for a new way to ...

Eli Lilly is evaluating a massive $5.9 billion biomanufacturing ... Meanwhile, the company is embroiled in a legal battle with Houston’s Empower Pharmacy over alleged copycat drugs, proving that ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

Eli Lilly & Co. and health tech company Kalderos Inc. are seeking to revive lawsuits in the DC Circuit after a federal judge ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from US rival Eli Lilly, makes inroads into its market share and as its pipeline of new ...